Birth Control Pills for Endometriosis

Home » Female » Birth Control Pills for Endometriosis

By



Attention: You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

This content is WordProof timestamped

Birth Control Pills for Endometriosis

Main article: Treatment of Endometriosis

For women with endometriosis, hormonal treatment such as birth control pills is the first-line treatment option usually recommended by doctors.1 Especially because the other treatment option, i.e. surgery, carries inherent risks including postoperative complications (e.g. infection and voiding dysfunction).2

However, birth control pills come in numerous formulations and types which can make choosing one a daunting process.

The 2 main types of birth control pills are:

  • Combined oral contraceptive pill (COCP).
  • Progestogen-only pill or progestin-only pill (POP), also known as the minipill.

Common COCP formulations include:

  • Ethinyl estradiol/Levonorgestrel
  • Ethinyl estradiol/Desogestrel
  • Ethinyl estradiol/Dydrogesterone
  • Ethinyl estradiol/Drospirenone
  • Estradiol valerate/Dienogest
  • Ethinyl estradiol/Dienogest

Progestogen-only pill formulations include:

  • Dienogest
  • Desorgestrel
  • Drospirenone

With so many choices it’s easy to get lost.

Not to mention a lack of comparative studies between formulations among women with endometriosis and evidence to common questions hidden in unrelated studies.

Lets try to answer some of these questions!

Taking birth control will not cause endometriosis.3 In fact, most experts agree that endometriosis is a congenital disorder which already exists at birth in some form or another.4

In saying that, endometriosis is also an estrogen-dependent disease which can be influenced by birth control depending on the formulation. Combined oral contraceptives which include estrogen can in theory promote the growth of endometriosis lesions. However, retrospective studies show this was only likely in past users of COCPs when estrogen doses were much higher.5

Birth control pills which contain estrogen can sometimes promote the growth of endometriosis and worsen symptoms.

This is most likely to occur in women who are progesterone resistant and or have increased estrogen levels above baseline after beginning birth control.

Birth control inhibits the growth of endometriosis for two-thirds of women. In the other one-third of women, birth control is not effective. Unfortunately this means for some women endometriosis will continue to grow while on birth control.

Birth control is effective in two-thirds of women with endometriosis. Birth control treatment normally takes 2 months (i.e. 2 menstrual cycles) to help relieve endometriosis-related symptoms including pain.6

Women who experience minimal or no change in endometriosis related symptoms after 3 months of birth control should speak to their doctor and discuss other treatment options.

The best birth control pill for endometriosis is the Combined Oral Contraceptive Pill (COCP) containing both estrogen and progesterone derivatives.7,8

However this recommendation does not apply to women diagnosed with only ovarian endometriosis due to a different biology.9,10 In these women, several studies report the best contraceptive pill is a progestogen-only pill (POP) such as dienogest.11,12 Although endometriomas do not grow during treatment with dienogest, significant regression is uncommon and surgery may be required eventually.13

Please note, like any medication there is potential side effects associated with oral contraceptive pills. This includes venous or arterial thrombosis (up to 11 cases per 10,000 women a year) and decreased bone mineral density depending on the formulation.14,15,16 Dienogest is also reported to significantly worsen the mood in some women.17 Please ask your doctor about these risks and how relevant they are to you.

The birth control pill is effective against all forms of endometriosis, but an intrauterine device (IUD) such as LNG-IUS is generally better for ovarian endometriosis post-surgery.18

This is because of its location and the set and forget nature of an IUD with studies reporting similar efficacy to birth control pills post-surgery but less side effects long term.19,20

Mirena, Liletta, Skyla and Kyleena all offer LNG-IUS (levonorgestrel-releasing intrauterine system) of varied doses and time period.

Breakthrough bleeding including spotting is common in women with endometriosis on the pill. In fact, at least 1 in 10 women with endometriosis still experience spotting after 5 years of combined oral contraceptive pill (COCP) or progestogen-only pill (POP) continued use.4

No, stopping birth control (or the pill) will not cause endometriosis. This is because endometriosis is a congenital disorder which already exists at birth in some form or another.3

Obviously, birth control is quite effective at managing endometriosis related symptoms. Therefore women who stop birth control and begin to experience these symptoms for the first time may believe that stopping birth control caused their endometriosis.

Birth control is not effective in one-third of women with endometriosis due to progesterone resistance or intolerance.21

In the other two-thirds of women, taking birth control for endometriosis, birth control will not stop working if taken continuously as directed.

In cases of intolerance, women with endometriosis are generally switched to a different birth control formulation or type. However, for women diagnosed with progesterone resistance (linked to inflammation)22 this strategy is ineffective requiring surgery or other medication to treat effectively.

Alternatives to birth control for the treatment of endometriosis include:

  • Analgesics (painkillers)
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Gonadotropin-releasing hormone (GnRH) agonists 23
  • Aromatase inhibitors
  • Laparoscopic surgery

For some women, these medications can manage endometriosis related symptoms well enough that surgery is not necessary.24

Summing up, the effect of birth control in woman with endometriosis will vary according to the type and formulation of birth control, severity of the disease, genetics and any comorbidities.

As a result, approximately 1 in 2 women will request a change in birth control, due to persisting pain, breakthrough bleeding, gain in weight, headaches or nausea.25

To quantify this better, your doctor may ask you to keep a daily diary of any symptoms and the level of discomfort using a visual analog scale (VAS).

Visual Analog Scale

This allows both you and your doctor to evaluate the efficacy of the recommended treatment with some degree of accuracy and compare it to other treatments in the future if need be.

Fortunately, research on alternative treatment options for endometriosis is growing exponentially, that using birth control to treat endometriosis may become a thing of the past very soon.

References

  1. Becker C M, et al. (2022). ESHRE guideline: endometriosis. https://academic.oup.com/hropen/article/2022/2/hoac009/6537540 ↩︎
  2. Leborne P, et al. (2022). Clinical outcomes following surgical management of deep infiltrating endometriosis. https://www.nature.com/articles/s41598-022-25751-9 ↩︎
  3. Vercellini P, et al. (2010). Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. https://academic.oup.com/humupd/article/17/2/159/692036 ↩︎
  4. Ober W B and Bernstein J, (1955). Observations on the endometrium and ovary in the newborn. https://pubmed.ncbi.nlm.nih.gov/13266459/ ↩︎
  5. Chapron C, et al. (2011). Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. https://academic.oup.com/humrep/article/26/8/2028/647686 ↩︎
  6. Uysal G, et al. (2018). A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. https://www.tandfonline.com/doi/full/10.1080/01443615.2017.1410533 ↩︎
  7. Troia L and Luisi S, et al. (2022). Estro-Progestins and Pain Relief in Endometriosis. https://www.mdpi.com/2673-396X/3/2/28 ↩︎
  8. Reis F, et al. (2020). Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. https://academic.oup.com/humupd/article/26/4/565/5837503 ↩︎
  9. Kalkan U, et al. (2022). T-Cadherin, E-Cadherin, PR-A, and ER-α Levels in Deep Infiltrating Endometriosis. https://pubmed.ncbi.nlm.nih.gov/35149616/ ↩︎
  10. Biyik I, et al. (2021). The deep infiltrating endometriosis tissue has lower T-cadherin, E-cadherin, progesterone receptor and oestrogen receptor than endometrioma tissue. https://www.sciencedirect.com/science/article/pii/S102845592100257 ↩︎
  11. Angioni S, et al. (2019). Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640674 ↩︎
  12. Wattanayingcharoenchai R, et al. (2021). Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.16366 ↩︎
  13. Malik R and Mann M K, (2021). Role of Dienogest in Endometriosis in Young Women. https://link.springer.com/article/10.1007/s13224-021-01483-0 ↩︎
  14. de Bastos M, et al. (2014). Combined oral contraceptives: venous thrombosis. https://doi.org/10.1002/14651858.CD010813.pub2 ↩︎
  15. Therapeutic Goods Administration, (2021). Update – Dienogest and risk of venous thromboembolism. https://www.tga.gov.au/news/safety-updates/update-dienogest-and-risk-venous-thromboembolism ↩︎
  16. Ebert A D, et al. (2017). Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents. https://www.jpagonline.org/article/S1083-3188(17)30036-0/fulltext ↩︎
  17. Dietrich H, et al. (2023). Endometriosis features and dienogest tolerability in women with depression: a case-control study. https://www.tandfonline.com/doi/full/10.1080/13625187.2023.2199899 ↩︎
  18. Morelli M, et al. (2013). Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.12030 ↩︎
  19. Kim H, et al. (2022). Long-term efficacy and safety of levonorgestrel-releasing intrauterine system as a maintenance treatment for endometriosis. https://journals.lww.com/md-journal/fulltext/2022/03110/long_term_efficacy_and_safety_of.28.aspx ↩︎
  20. Lee K H, et al. (2018). Comparison of the efficacy of diegnogest and levonorgestrel-releasing intrauterine system after laparoscopic surgery for endometriosis. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.13703 ↩︎
  21. Donnez J and Dolmans M M, et al. (2021). Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review. https://www.mdpi.com/2077-0383/10/5/1085 ↩︎
  22. Wang Y, et al. (2023). Distinct subtypes of endometriosis identified based on stromal-immune microenvironment and gene expression: implications for hormone therapy. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1133672/full ↩︎
  23. Leyland N, et al. (2020). A clinician’s guide to the treatment of endometriosis with elagolix. https://www.liebertpub.com/doi/10.1089/jwh.2019.8096 ↩︎
  24. Vannuccini S, et al. (2021). Hormonal treatments for endometriosis: The endocrine background. https://link.springer.com/article/10.1007/s11154-021-09666-w ↩︎
  25. da Costa Pinheiro, et al. (2023). Tolerability of endometriosis medical treatment: a comparison between combined hormonal contraceptives and progestins. https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-023-02647-y ↩︎

Questions or comments?